Industry & Business

Diaceutics signs multi-million-euro partnership with BioReference Laboratories

 Breaking News
  • TechConnect Live – RDS, Dublin – May 30th, 2018 TechConnect Live, Ireland’s largest technology event, is expected to attract over 3,000 visitors from across the Irish and international tech sector to the RDS, Dublin on 30th of May 2018. TechConnect Live provides a unique forum for technology companies, start-ups, investors and the largest Irish and global end users of technology and services in order [...]...
  • Ornua Delivers Record Revenue Ornua, Ireland’s largest exporter of Irish dairy products which supplies to over 110 countries worldwide, has reported record revenue of €2.1 billion for the year ended 30 December 2017. It marks the first year of Ornua’s new five-year growth plan, ‘Ornua 2021’, which positions the business as a leading global dairy organisation that delivers results [...]...
  • EPA Welcomes Increase in Composting and Anaerobic Digestion of Waste The EPA has released data and information on composting and anaerobic digestion in Ireland for 2016. The data updates the National Waste Statistics web resource, launched by the EPA in recent months. Commenting on the figures, Stephen Treacy, EPA, said: “The EPA welcomes the increase in the amount of biodegradable waste being accepted for recycling at composting [...]...
  • Revised Research Priority Areas For 2018-2023 The Government has published the ‘Research Priority Areas 2018–2023’ report. Research Prioritisation, introduced by the Government in 2012, aligns the majority of competitively awarded public investment in research with 14 priority areas. Innovation 2020, Ireland’s strategy for research and development, science and technology, commits to reviewing the priority areas to ensure that they are still valid [...]...
  • Brexit Price Increases Could Affect Poorer Households Most A hard Brexit would increase the cost of living for all households in Ireland by 2 per cent to 3.1 per cent – an annual increase of €892 to €1,360 per household, according to the Competition and Consumer Protection Commission. Costs would rise the most for lower-income households. These households spend a greater share of [...]...

Diaceutics signs multi-million-euro partnership with BioReference Laboratories

Diaceutics signs multi-million-euro partnership with BioReference Laboratories
April 25
09:00 2017

Irish data insights and solutions company Diaceutics has announced a five-year multi-million-euro partnership with US-based BioReference Laboratories. The partnership will see Diaceutics acquire real-time testing data from BioReference, allowing it to help pharmaceutical companies achieve faster rollouts of new drugs through better understanding of the US diagnostics market.

Through its partnership with BioReference, which works with 30,000 healthcare providers across the US, Diaceutics will have access to data from 50,000 patient samples per day. Coupled with insights from BioReference, the real-time data will help improve patient testing by ensuring that pharmaceutical companies better understand the testing patterns of physicians considering precision medicine therapies for patients.

Currently, Diaceutics estimates that pharmaceutical companies are missing out on more than 20% of cancer patients every year in the US due to the challenging diagnostic landscape. With 70% of new drugs in the next five years expected to be test-dependent, Diaceutics expects that percentage will increase.

Peter Keeling, CEO, Diaceutics, said: “Diagnostic data from laboratories like BioReference helps pharmaceutical companies better understand the testing journey that patients go on in the often difficult search for a targeted therapy. That information allows pharma to pinpoint patients that need to be on a specific – and often life-changing – drug, accelerate speed to market for new drugs and improve patient outcomes.”

Diaceutics will integrate the data gathered from BioReference with its existing lab data accumulated through partnerships with other labs. Together, the data will allow Diaceutics to provide pharma with more complete, aggregated testing data that meets their very specific requirements – helping them to close the 20% patient gap in the oncology testing market and achieve a better return on new drug investments.

Keeling continues: “Timing is key for many patients Diaceutics strives to increase the number of patients correctly tested, therefore increasing the demand for new drugs – an attractive prospect for pharmaceutical companies – and ultimately significantly improving patient outcomes.

“We have seen first-hand the improved decision-making by our pharma clients when presented with the relevant data trends in specific disease areas. Enriching our real time and retrospective analytics with BioReference’s knowledgebase allows us to further map the diagnostic journey of patients and help pharmaceutical companies better understand how testing impacts precision prescribing. With this information, we can simply enable better decision making and investment in patient, physician and laboratory education.”

About Author



Related Articles

New Subscriber

Subscribe Here


National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories

Upcoming Events

  • No upcoming events
AEC v1.0.4